Oslo University Hospital HF
Oslo University Hospital HF is recorded as a service provider in 14 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 14 of 14 trials · Latest update first
ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) with Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)
Sponsor Karolinska University Hospital
- Start (EU)
- Latest update
- Estimated end
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 - A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group - IntReALL BCP 2020
Sponsor Charite Universitaetsmedizin Berlin KöR
- Start (EU)
- Not reported
- Latest update
- Estimated end
A phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive at the end of consolidation (EOC) therapy
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
HOVON 169 CAD: Phase II trial of Zanubrutinib in primary Cold Agglutinin Disease. CaZa study
Sponsor Haemato Oncology Foundation For Adults Netherlands
- Start (EU)
- Latest update
- Estimated end
- Not reported
European Randomised Clinical Trial on mPOX Infection (EPOXI)
Sponsor University Medical Center Utrecht
- Start (EU)
- Latest update
- Estimated end
- Not reported
A multi-center, open, randomized, 18-month, parallel-group, superiority study to compare the effect of proactive therapeutic drug monitoring versus standard of care with regards to maintenance of sustained disease control without flare in adults with rheumatoid arthritis treated with a subcutaneous tumor necrosis factor inhibitor
Sponsor Diakonhjemmet Sykehus AS
- Start (EU)
- Latest update
- Estimated end
Ventricular water absorption capacity in hydrocephalus
Sponsor Oslo University Hospital HF
- Start (EU)
- Latest update
- Estimated end
- Not reported
Acalabrutinib and rituximab in elderly patients with untreated mantle cell lymphoma (ALTAMIRA)
Sponsor Region Skane
- Start (EU)
- Latest update
- Estimated end
Intrathecal MRI Contrast for Assessment of CSF Transport
Sponsor Oslo University Hospital HF
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Norwegian trial Comparing Treatment Strategies for Carpal Tunnel Syndrome
Sponsor Diakonhjemmet Sykehus AS
- Start (EU)
- Latest update
- Estimated end
- Not reported
TRIANGLE - autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European mcl network trial
Sponsor Klinikum der Universitaet Muenchen AöR
- Start (EU)
- Latest update
- Estimated end
HD21 for advanced stages - Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 4-6 cycles of escalated BEACOPP with 4-6 cycles of BrECADD
Sponsor University Of Cologne
- Start (EU)
- Latest update
- Estimated end
ENRICH - Randomised, open label study of Rituximab/Ibrutinib vs Rituximab/Chemotherapy in older patients with untreated mantle cell lymphoma
Sponsor Region Skane
- Start (EU)
- Latest update
- Estimated end
Treatment of frontal fibrosing alopecia with microneedling and photodynamic therapy using 5-aminolevulinic acid in male and female adult participants – an open single group phase 2 study
Sponsor Oslo University Hospital HF
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Oslo University Hospital HF?
The 2026-10-09 snapshot links Oslo University Hospital HF to 14 distinct CTIS trials. Recorded services include Clinical monitoring, Project management, Laboratory services, Data management, among 7 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Oslo University Hospital HF?
The most frequently recorded therapeutic areas are Haematological Malignancies. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Oslo University Hospital HF conducted?
The linked trials record locations in 20 countries, including Norway, Denmark, Sweden, Netherlands, Belgium. These are trial locations, not confirmed office locations or countries where Oslo University Hospital HF delivered services.
What can this page tell me about Oslo University Hospital HF's trial experience?
Browse 14 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Oslo University Hospital HF. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Oslo University Hospital HF